SCHEMBL29602749

SCHEMBL29602749

CN1CCc2cc(O)cc3c2C1Cc1ccc(O)c(O)c1-3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 1.00
ALDH1A1 P00352 4/20 1.00
MAPT P10636 4/20 1.00
MAPK1 P28482 3/20 1.00
RGS12 O14924 2/20 1.00
CYP1A2 P05177 2/20 1.00
NFKB1 P19838 2/20 1.00
THPO P40225 2/20 1.00
MTOR P42345 2/20 1.00
GNAI1 P63096 2/20 1.00
HIF1A Q16665 2/20 1.00
HSD17B10 Q99714 2/20 1.00
PKM P14618 1/20 1.00
KDM4E B2RXH2 2/20 0.98
LMNA P02545 2/20 0.98
HPGD P15428 2/20 0.98
PMP22 Q01453 2/20 0.98
KMT2A Q03164 2/20 0.98
NPSR1 Q6W5P4 2/20 0.98
GMNN O75496 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL140170 1.00 DRD2 (1.00) DRD2ALDH1A1MAPTMAPK1RGS12
SCHEMBL107293 1.00 DRD2 (1.00) DRD2ALDH1A1MAPTMAPK1RGS12
SCHEMBL8344207 1.00 DRD2 (1.00) DRD2ALDH1A1MAPTMAPK1RGS12
Bromide SCHEMBL31027963 0.99 MAPT (1.00) DRD2ALDH1A1MAPTMAPK1RGS12
Bromide SCHEMBL4923286 0.99 MAPT (1.00) DRD2ALDH1A1MAPTMAPK1RGS12
Bromide SCHEMBL4923294 0.99 MAPT (1.00) DRD2ALDH1A1MAPTMAPK1RGS12
SCHEMBL12877906 0.89 DRD2 (0.80) DRD2ALDH1A1MAPTMAPK1RGS12
SCHEMBL518062 0.86 ALDH1A1 (1.00) DRD2ALDH1A1MAPTMAPK1RGS12
SCHEMBL8097389 0.86 DRD1 (0.77) DRD2ALDH1A1MAPTMAPK1RGS12
SCHEMBL1325960 0.86 MAPT (1.00) DRD2ALDH1A1MAPTMAPK1RGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4378532-B1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUND MEDICAL EDUCATION & RES (US) 2025-11-12 EP claimed
EP-3745862-B1 D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUND MEDICAL EDUCATION & RES (US) 2024-06-26 EP claimed
EP-4378532-B1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUND MEDICAL EDUCATION & RES (US) 2025-11-12 EP disclosed
US-20250179086-A1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2025-06-05 US disclosed
US-12264163-B2 Compounds and methods for treating fibrotic pathologies MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2025-04-01 US disclosed
US-20240252463-A1 METHODS OF TREATING FIBROTIC PATHOLOGIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-08-01 US disclosed
EP-4378532-A2 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES Mayo Foundation for Medical Education and Research (US) 2024-06-05 EP disclosed
EP-4003348-B1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUND MEDICAL EDUCATION & RES (US) 2024-04-03 EP disclosed
EP-4284507-A1 METHODS OF TREATING OCULAR FIBROTIC PATHOLOGIES Mayo Foundation for Medical Education and Research (US) 2023-12-06 EP disclosed
US-20230346740-A1 METHODS OF TREATING FIBROTIC PATHOLOGIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2023-11-02 US disclosed
US-20220275002-A1 Compounds And Methods For Treating Fibrotic Pathologies MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2022-09-01 US disclosed
WO-2022164996-A1 METHODS OF TREATING OCULAR FIBROTIC PATHOLOGIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2022-08-04 WO disclosed
EP-4003348-A1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES Mayo Foundation for Medical Education and Research (US) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179086-A1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MMP1, MMP8, COL2A1 DRD2 4882/4885ALDH1A1 433/4885MAPT 3368/4885
US-12264163-B2 Compounds and methods for treating fibrotic pathologies MMP1, MMP8, COL2A1 DRD2 4882/4885ALDH1A1 433/4885MAPT 3368/4885
US-20240252463-A1 METHODS OF TREATING FIBROTIC PATHOLOGIES MMP1, MMP8, COL2A1 DRD2 4879/4885ALDH1A1 1390/4885MAPT 3670/4885
US-20220275002-A1 Compounds And Methods For Treating Fibrotic Pathologies MMP1, MMP8, COL2A1 DRD2 4882/4885ALDH1A1 433/4885MAPT 3368/4885
US-20230346740-A1 METHODS OF TREATING FIBROTIC PATHOLOGIES MMP1, MMP8, COL2A1 DRD2 4879/4885ALDH1A1 1390/4885MAPT 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.